Amlodipine alters hemorheological parameters: Increased efficacy at the cost of edema?
Amlodipine
/ administration & dosage
Blood Viscosity
/ drug effects
Calcium Channel Blockers
/ administration & dosage
Dose-Response Relationship, Drug
Edema
/ blood
Erythrocyte Aggregation
/ drug effects
Healthy Volunteers
Hematocrit
Humans
Hypertension
/ blood
Male
Single-Blind Method
Treatment Outcome
Young Adult
Blood viscosity
Calcium blockers
Data analytics
Hypertension
Journal
Indian heart journal
ISSN: 2213-3763
Titre abrégé: Indian Heart J
Pays: India
ID NLM: 0374675
Informations de publication
Date de publication:
Historique:
received:
04
09
2018
revised:
28
10
2018
accepted:
29
10
2018
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
5
9
2019
Statut:
ppublish
Résumé
Despite several decades of use of calcium channel blockers, the side effect of edema persists as a class effect, and its mechanism is unresolved. Amlodipine has effects on hemorheology (HR), and its hemodilutory property may partly contribute to its antihypertensive action. This aspect is not well studied, and the literature is sparse in this regard. This experiment was planned to determine effect of a single-dose administration of amlodipine on HR parameters in normal human volunteers. Amlodipine (5 mg) or S (-) amlodipine (2.5 mg) was administered to 27 normal human volunteers. Whole-blood viscosity (WBV) at different shear rates, plasma viscosity (PV), red cell rigidity (RCR), red cell aggregation (RCA), hematocrit (Hct), plasma hemoglobin, along with plasma drug concentration were determined at time intervals, t = 0, 4, 8, 12, and 24 h. Statistically significant reductions were observed at t Amlodipine causes a reduction in Hct and blood viscosity, along with hemodilution. These effects persist as long as the drug remains in plasma. Edema resulting from chronic dosing may be explained by the aforementioned effects. It is possible that antihypertensive action of the drug may be due to a combination of vasodilatation and an improvement in the HR properties.
Sections du résumé
BACKGROUND
BACKGROUND
Despite several decades of use of calcium channel blockers, the side effect of edema persists as a class effect, and its mechanism is unresolved. Amlodipine has effects on hemorheology (HR), and its hemodilutory property may partly contribute to its antihypertensive action. This aspect is not well studied, and the literature is sparse in this regard.
OBJECTIVE
OBJECTIVE
This experiment was planned to determine effect of a single-dose administration of amlodipine on HR parameters in normal human volunteers.
METHODS AND RESULTS
RESULTS
Amlodipine (5 mg) or S (-) amlodipine (2.5 mg) was administered to 27 normal human volunteers. Whole-blood viscosity (WBV) at different shear rates, plasma viscosity (PV), red cell rigidity (RCR), red cell aggregation (RCA), hematocrit (Hct), plasma hemoglobin, along with plasma drug concentration were determined at time intervals, t = 0, 4, 8, 12, and 24 h. Statistically significant reductions were observed at t
CONCLUSIONS
CONCLUSIONS
Amlodipine causes a reduction in Hct and blood viscosity, along with hemodilution. These effects persist as long as the drug remains in plasma. Edema resulting from chronic dosing may be explained by the aforementioned effects. It is possible that antihypertensive action of the drug may be due to a combination of vasodilatation and an improvement in the HR properties.
Identifiants
pubmed: 31000180
pii: S0019-4832(18)30576-5
doi: 10.1016/j.ihj.2018.10.417
pmc: PMC6477139
pii:
doi:
Substances chimiques
Calcium Channel Blockers
0
Amlodipine
1J444QC288
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-38Informations de copyright
Copyright © 2018 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
Références
Am J Hypertens. 1999 Jul;12(7):739-43
pubmed: 10411372
Clin Hemorheol Microcirc. 1999;21(3-4):195-200
pubmed: 10711743
Clin Hemorheol Microcirc. 1999;21(3-4):209-16
pubmed: 10711745
Int J Cardiol. 2001 May;78(3):241-6
pubmed: 11376827
Clin Hemorheol Microcirc. 2002;26(2):81-3
pubmed: 12082255
Clin Hemorheol Microcirc. 2002;26(2):125-35
pubmed: 12082261
J Hypertens. 2003 Nov;21(11):1983-92
pubmed: 14597836
Clin Hemorheol Microcirc. 2005;33(2):121-6
pubmed: 16151259
J Biomed Eng. 1991 Sep;13(5):441-3
pubmed: 1795515
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Blood Press. 2015 Feb;24(1):55-60
pubmed: 25390761
J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):121-30
pubmed: 25398848
Clin Hemorheol Microcirc. 2018;68(4):371-382
pubmed: 29036797
Indian J Pharmacol. 2017 Jul-Aug;49(4):312-316
pubmed: 29326492
Exp Ther Med. 2018 Apr;15(4):3809-3814
pubmed: 29581738
Am J Med. 1981 Jun;70(6):1195-1202
pubmed: 7234890
Circulation. 1993 Jun;87(6):1915-20
pubmed: 8504504
J Hum Hypertens. 1996 Mar;10(3):199-205
pubmed: 8733040
Clin Hemorheol Microcirc. 1997 May-Jun;17(3):193-8
pubmed: 9356783
Clin Hemorheol Microcirc. 1997 Nov-Dec;17(6):397-420
pubmed: 9502525
Fundam Clin Pharmacol. 1998;12(4):457-62
pubmed: 9711470